CreativeOne Wealth LLC Boosts Stock Position in DaVita Inc. (NYSE:DVA)

CreativeOne Wealth LLC boosted its position in shares of DaVita Inc. (NYSE:DVA) by 12.3% during the third quarter, Holdings Channel.com reports. The fund owned 3,314 shares of the company’s stock after acquiring an additional 363 shares during the quarter. CreativeOne Wealth LLC’s holdings in DaVita were worth $543,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its position in shares of DaVita by 0.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 85,286 shares of the company’s stock valued at $11,775,000 after purchasing an additional 533 shares during the period. B. Riley Wealth Advisors Inc. lifted its position in shares of DaVita by 9.9% in the first quarter. B. Riley Wealth Advisors Inc. now owns 2,308 shares of the company’s stock valued at $319,000 after acquiring an additional 207 shares in the last quarter. Comerica Bank boosted its stake in shares of DaVita by 41.4% in the first quarter. Comerica Bank now owns 34,431 shares of the company’s stock worth $4,753,000 after acquiring an additional 10,074 shares during the period. Swedbank AB bought a new stake in DaVita during the 1st quarter valued at approximately $1,283,000. Finally, Cetera Advisors LLC purchased a new position in DaVita in the 1st quarter worth approximately $448,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Stock Up 0.3 %

Shares of NYSE DVA opened at $166.17 on Monday. The stock has a market capitalization of $13.63 billion, a price-to-earnings ratio of 17.93, a P/E/G ratio of 0.94 and a beta of 0.89. DaVita Inc. has a 12-month low of $99.18 and a 12-month high of $169.51. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78. The firm’s 50-day moving average price is $158.57 and its 200-day moving average price is $149.39.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing the consensus estimate of $2.76 by ($0.17). The firm had revenue of $3.26 billion during the quarter, compared to analysts’ expectations of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. The company’s revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the company posted $2.85 EPS. On average, equities research analysts anticipate that DaVita Inc. will post 9.71 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Bank of America lifted their price objective on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research report on Wednesday, August 7th. Barclays boosted their price target on shares of DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Truist Financial raised their price objective on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Finally, UBS Group boosted their target price on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, DaVita currently has an average rating of “Hold” and an average price target of $161.80.

Insider Buying and Selling at DaVita

In related news, CEO Javier Rodriguez sold 9,881 shares of the business’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $162.85, for a total transaction of $1,609,120.85. Following the completion of the transaction, the chief executive officer now owns 887,835 shares in the company, valued at $144,583,929.75. The trade was a 1.10 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 2.00% of the company’s stock.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.